Frequency of hospitalization after exposure to known drug-drug interactions in a Medicaid population

Pharmacotherapy

Volumn 18, Issue 5, 1998, Pages 1112-1120

  Hamilton, Robert A ^a   Briceland, Laurie L ^a   Andritz, Mary H ^b  

^a ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^b Capitol   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; ANTIHISTAMINIC AGENT; BARBITURIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CAPTOPRIL; CARBAMAZEPINE; CIMETIDINE; DIGITALIS; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; FLUOXETINE; GASTROINTESTINAL AGENT; GLUCOCORTICOID; ISONIAZID; LISINOPRIL; MACROLIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PENICILLIN DERIVATIVE; PHENYTOIN; POTASSIUM; RIFAMPICIN; SALICYLIC ACID; SEROTONIN UPTAKE INHIBITOR; SULFONAMIDE; THEOPHYLLINE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VERAPAMIL; WARFARIN;

ADOLESCENT; ADULT; AGED; ARTICLE; CASE CONTROL STUDY; CHILD; DRUG INDUCED DISEASE; DRUG MONITORING; FEMALE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAID; PHARMACOEPIDEMIOLOGY; RISK ASSESSMENT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; DRUG INTERACTIONS; FEMALE; HOSPITALIZATION; HUMANS; IATROGENIC DISEASE; MALE; MEDICAID; MIDDLE AGED; NEW YORK; PHARMACEUTICAL PREPARATIONS; UNITED STATES;

EID: 0031688472     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Jankel CA, Fitterman LK. Epidemiology of drug-drug interactions as cause of hospital admissions. Drug Saf 1993;9(1):51-9.
2. Schneitman-McIntire O, Farnen TA, Gordon N, et al. Medication misadventures resulting in emergency department visits at an HMO medical center. Am J Health-Syst Pharm 1996;53:1416-22.
3. Johnson JA, Bootman JL. Drug-related morbidity and mortality. A cost-of-illness model. Arch Intern Med 1995;155:1949-56.
4. Zucchero FJ, Hogen MJ, Evaluations of drug interactions. St. Louis: Hearst Corp., 1995.
5. Hansten PD, Horn JR, Koda-Kimble MAS, Young LY. Drug interactions and updates quarterly. Vancouver, WA: Applied Therapeutics, 1993.
6. McEvoy GK, ed. AHFS 96 drug information. Bethesda, MD: American Society of Health-System Pharmacists, 1996.
7. DiPiro JT, Talbert RL, Hayes PE, Yee GD, Matzke GR, Posey LM. Pharmacotherapy, 3rd ed. Norwalk, CT: Appleton & Lange, 1997.
8. Young LY, Koda-Kimble MA, eds. Applied therapeutics, 6th ed. Vancouver, WA: Applied Therapeutics, 1995.
9. Davis RL, Quenzer RW, Kelly HW, Powell JR. Effect of the addition of ciprofloxacin on theophylline pharmacokinetics in subjects inhibited by cimetidine. Ann Pharmacother 1992;26:11-13.
10. Greenblatt DJ, Preskorn SH, Cotreau MM, Horst WD, Harmatz JS. Fluoxetine impairs clearance of alprazolam but not of clonazepam. Clin Pharmacol Ther 1992;52:479-86.
11. Honig PK, Wortham DC, Zamani K, Conner DP, Mullin JC, Cantilena LR. Terfenadine-ketoconazole interaction. JAMA 1993;269:1513-18.
12. Woosley RL, Chen Y, Freiman JP, Gillis RA. Mechanism of the cardiotoxic actions of terfenadine. JAMA 1993;269:1532-6.
13. Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, Gilman AG, eds. Goodman and Gilman's the pharmacological basis of therapeutics, 9th ed. New York: McGraw-Hill, 1996.
14. Derby LE, Jick SS, Langlois JC, et al. Hospital admission for xanthine toxicity. Pharmacotherapy 1990;10:112-14.
15. Hamilton RA, Gordon T. Incidence and cost of hospital admissions secondary to drug interactions involving theophylline. Ann Pharmacother 1992;26:1507-11.
16. Department of Health and Human Services. Medicaid program; drug use review program and electronic claims management system for outpatient drug claims. Federal Register 1992;57:49401.
17. Hennekens CH, Buring JE. Epidemiology in medicine. Boston: Little, Brown, 1987:295-304.
18. Nahata M. Drug interactions with azithromycin and the macrolides: an overview. J Antimicrob Chemother 1996;37(suppl C):133-42.
19. McCaig LF, Hughes JM. Trends in antimicrobial drug prescribing among office-based physicians in the United States. JAMA 1995;273:214-19.
20. Lindenbaum J, Tse-eng D, Butler VP, Rund DG. Urinary excretion of reduced metabolites of digoxin. Am J Med 1981;71:67-74.